| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature medicine 27 (10), 1752-1760, 2021 | 458 | 2021 |
| Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison IE Galani, N Rovina, V Lampropoulou, V Triantafyllia, M Manioudaki, ... Nature Immunology 22 (1), 32-40, 2021 | 447 | 2021 |
| The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when, and how I Karaiskos, S Lagou, K Pontikis, V Rapti, G Poulakou Frontiers in public health 7, 460782, 2019 | 283 | 2019 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 132 | 2022 |
| Endothelial dysfunction in acute and long standing COVID− 19: A prospective cohort study E Oikonomou, N Souvaliotis, S Lampsas, G Siasos, G Poulakou, ... Vascular Pharmacology 144, 106975, 2022 | 82 | 2022 |
| Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19 M Psichogiou, A Karabinis, ID Pavlopoulou, D Basoulis, K Petsios, ... PLoS One 15 (12), e0243025, 2020 | 68 | 2020 |
| The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A … PC Fragkou, G Poulakou, A Blizou, M Blizou, V Rapti, ... Microorganisms 7 (6), 159, 2019 | 64 | 2019 |
| Autoantibodies against type I IFNs in patients with critical influenza pneumonia Q Zhang, A Pizzorno, L Miorin, P Bastard, A Gervais, T Le Voyer, L Bizien, ... Journal of Experimental Medicine 219 (11), e20220514, 2022 | 51 | 2022 |
| Circulation of pertussis and poor protection against diphtheria among middle-aged adults in 18 European countries G Berbers, P van Gageldonk, J van de Kassteele, U Wiedermann, ... Nature Communications 12 (1), 2871, 2021 | 46 | 2021 |
| Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs P Bastard, SE Vazquez, J Liu, MT Laurie, CY Wang, A Gervais, ... Science immunology 8 (90), eabp8966, 2023 | 45 | 2023 |
| The association of baseline plasma SARS-CoV-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19 ACTIV-3/TICO Study Group Annals of internal medicine 175 (10), 1401-1410, 2022 | 33 | 2022 |
| Beneficial effects of intermediate dosage of anticoagulation treatment on the prognosis of hospitalized COVID-19 patients: the ETHRA study G Poulakou, E Dimakakos, A Kollias, KG Kyriakoulis, V Rapti, I Trontzas, ... in vivo 35 (1), 653-661, 2021 | 27 | 2021 |
| Efficacy and safety of ensovibep for adults hospitalized with COVID-19: a randomized controlled trial ACTIV-3/TICO Study Group* Annals of internal medicine 175 (9), 1266-1274, 2022 | 20 | 2022 |
| The “Old” and the “New” antibiotics for MDR Gram-negative pathogens: For whom, when, and how. Front Public Health. 2019; 7: 151 I Karaiskos, S Lagou, K Pontikis, V Rapti, G Poulakou | 19 | 2019 |
| High versus standard intensity of thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis A Kollias, KG Kyriakoulis, IP Trontzas, V Rapti, IG Kyriakoulis, ... Journal of Clinical Medicine 10 (23), 5549, 2021 | 17 | 2021 |
| Author correction: early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature Medicine 27 (10), 1850-1850, 2021 | 12 | 2021 |
| Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in … HC Maltezou, D Basoulis, K Bonelis, MN Gamaletsou, TV Giannouchos, ... Vaccine 41 (14), 2343-2348, 2023 | 8 | 2023 |
| New insights into SARS-CoV-2 and cancer cross-talk: Does a novel oncogenesis driver emerge? V Rapti, T Tsaganos, IA Vathiotis, NK Syrigos, P Li, G Poulakou Vaccines 10 (10), 1607, 2022 | 8 | 2022 |
| Delineating the SARS-CoV-2 induced interplay between the host immune system and the DNA damage response network C Papanikolaou, V Rapti, D Stellas, DT Stefanou, K Syrigos, GN Pavlakis, ... Vaccines 10 (10), 1764, 2022 | 7 | 2022 |
| Knowledge and perceptions about COVID-19 among health care workers: evidence from COVID-19 hospitals during the second pandemic wave P Ioannou, S Karakonstantis, A Mathioudaki, A Sourris, V Papakosta, ... Tropical Medicine and Infectious Disease 6 (3), 136, 2021 | 6 | 2021 |
